Dosing & Uses
Males (14-50 years old): 35 mcg/day; (> 50 years old): 30 mcg/day;
Females (19-50 years old): 25 mcg/day; (>50 years old): 20 mcg/day;
Pregnant 30 mcg/day;
Lactation 45 mcg/day
Diabetes Mellitus, Type 2
200-1000 mcg/day PO in divided doses
Beta Blocker-Related Low HDL Cholesterol
200 mcg PO TID
200 mcg PO TID, OR
400 mcg PO qDay
200 mcg PO qDay
200 mcg PO qDay-BID
Other Indications & Uses
Weight loss, type 2 diabetes, hypercholesterolemia, athletic performance enhancement, dysthymic disorder, hyperglycemia, hypoglycemia (reactive), low HDL cholesterol (beta blocker-related), muscle mass builder
- Possibly effective in lowering blood lipids, maintaining glycemic control
- Likely ineffective for weight loss
0-6 months old: 0.2 mcg/day
7-12 months old: 5.5 mcg/day
1-3 years old: 11 mcg/day
4-8 years old: 15 mcg/day
9-13 years old: 21 mcg/day (female), 25 mcg/day (male)
14-18 years old (female): 21 mcg/day
Polycystic Ovary Syndrome (Orphan)
Orphan designation for chromium picolinate and chromium histidinate for treatment of pediatic polycystic ovary syndrome (aged ≤16 yr)
- JDS Therapeutics, LLC; 3 Manhattanville Rd, Suite 201; Purchase, NY 10577
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
- Cognitive dysfunction, headache, insomnia, irritability, mood changes, motor dysfunction, perceptual dysfunction, sleep disturbances
- Weight gain (high dose)
- Anemia, hemolysis, thrombocytopenia
- Renal/liver impairment (high dose)
Chromate allergy, leather contact allergy, impaired renal fxn, breastfeeding (high dose)
Psychiatric or behavioral disorders (high dose)
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Excretion: renal, biliary
Mechanism of Action
Enhances insulin receptor sensitivity in peripheral cells (component of glucose tolerance factor)